Title Clinical statistical investigation of cleft lip and palate patients
... Since the fee for orthodontic treatment of malocclusion caused by cleft lip and palate (CLP) became covered by national health insurance in 1982, orthodontic treatment from school age has become the norm. However, in some CLP patients, orthodontic treatment is commenced in adulthood. A number of stu ...
... Since the fee for orthodontic treatment of malocclusion caused by cleft lip and palate (CLP) became covered by national health insurance in 1982, orthodontic treatment from school age has become the norm. However, in some CLP patients, orthodontic treatment is commenced in adulthood. A number of stu ...
Podcast of the Journal of Clinical Sleep Medicine
... episodes of nocturnal gastroesophageal reflux versus only 2% those without aerophagia. Conversely, those with gastroesopha- ...
... episodes of nocturnal gastroesophageal reflux versus only 2% those without aerophagia. Conversely, those with gastroesopha- ...
2013 Royal College of Obstetricians and
... published their study in 2008 which demonstrated that the risk of breast cancer among postmenopausal women receiving combination HRT varied significantly according the type of progestogen used. However, while this study was very large including over 80 000 participants, interpretation of its data is ...
... published their study in 2008 which demonstrated that the risk of breast cancer among postmenopausal women receiving combination HRT varied significantly according the type of progestogen used. However, while this study was very large including over 80 000 participants, interpretation of its data is ...
as diaspartate - Therapeutic Goods Administration
... Novartis Pharmaceuticals Australia Pty Ltd has applied to register pasireotide (as diaspartate), Signifor, a new chemical entity for the treatment of Cushing’s disease in adults. Treatment involves twice daily sc injection. The maximum recommended human dose is 900 μg/day BD. The overall quality of ...
... Novartis Pharmaceuticals Australia Pty Ltd has applied to register pasireotide (as diaspartate), Signifor, a new chemical entity for the treatment of Cushing’s disease in adults. Treatment involves twice daily sc injection. The maximum recommended human dose is 900 μg/day BD. The overall quality of ...
Current and novel therapeutics in the treatment of systemic lupus erythematosus
... SLE, especially at the beginning of a flare. They have strong antiinflammatory effects on both acquired and innate immune pathways. They inhibit B- and T-cell responses and effector functions of monocytes and neutrophils through inhibition of nuclear factor kB activity.5 In patients with lupus, gluc ...
... SLE, especially at the beginning of a flare. They have strong antiinflammatory effects on both acquired and innate immune pathways. They inhibit B- and T-cell responses and effector functions of monocytes and neutrophils through inhibition of nuclear factor kB activity.5 In patients with lupus, gluc ...
Laughter..the best medicine!
... Available scientific evidence does not support humour as an effective treatment for cancer or any other disease; however, laughter has many benefits, including positive physical changes and an overall sense of well being. The healing power of humour has been long been recognized but only in the past ...
... Available scientific evidence does not support humour as an effective treatment for cancer or any other disease; however, laughter has many benefits, including positive physical changes and an overall sense of well being. The healing power of humour has been long been recognized but only in the past ...
1: gastro-intestinal system
... salivation occurs at lower doses than required for other antimuscarinic effects.4 This reduces the likelihood of undesirable effects when antimuscarinics are given to reduce salivation. In some patients, a reduction in excess saliva results in improved speech.5 To reduce the risk of undesirable effe ...
... salivation occurs at lower doses than required for other antimuscarinic effects.4 This reduces the likelihood of undesirable effects when antimuscarinics are given to reduce salivation. In some patients, a reduction in excess saliva results in improved speech.5 To reduce the risk of undesirable effe ...
The Use of Virtual Reality Technology in the Treatment of - E
... vivo exposures can be costly (e.g., an actual flight) or impractical to conduct (e.g., combat in Iraq or Afghanistan), whereas VR approaches allow for an inexpensive approach and the possibility of constructing exposures that may be difficult to implement in vivo. VRE provides the opportunity to man ...
... vivo exposures can be costly (e.g., an actual flight) or impractical to conduct (e.g., combat in Iraq or Afghanistan), whereas VR approaches allow for an inexpensive approach and the possibility of constructing exposures that may be difficult to implement in vivo. VRE provides the opportunity to man ...
54 Antihistamines in Atopic Eczema
... reported tests included in the above-mentioned ETAC study. It was shown that there were no differences between cetirizine high-dose treatment (0.25 mg/kg twice daily) and placebo in terms of behavior, cognitive, and psychomotor development or learning processes. In conclusion, it can be summarized t ...
... reported tests included in the above-mentioned ETAC study. It was shown that there were no differences between cetirizine high-dose treatment (0.25 mg/kg twice daily) and placebo in terms of behavior, cognitive, and psychomotor development or learning processes. In conclusion, it can be summarized t ...
Slide 1
... Do not always bring up symptoms • May be due to lack of knowledge (considered “a natural part of aging”) • May be due to embarrassment If they do, ...
... Do not always bring up symptoms • May be due to lack of knowledge (considered “a natural part of aging”) • May be due to embarrassment If they do, ...
Direct-acting antiviral drugs for the treatment of hepatitis C
... that these drugs are cost effective and, significantly, they are curative – they are not a salve to give you added months or years of survival. The scope of this development is potentially the hottest potato from a financial perspective for all healthcare environments, particularly the NHS, because ...
... that these drugs are cost effective and, significantly, they are curative – they are not a salve to give you added months or years of survival. The scope of this development is potentially the hottest potato from a financial perspective for all healthcare environments, particularly the NHS, because ...
Adalimumab for Severe Refractory Uveitis
... caused the condition. First line therapy for such cases is with corticosteroids, usually in the form of prednisolone tablets. Corticosteroids have the important advantage of working quickly but have numerous side-effects especially at higher doses. For some patients, especially where only one eye is ...
... caused the condition. First line therapy for such cases is with corticosteroids, usually in the form of prednisolone tablets. Corticosteroids have the important advantage of working quickly but have numerous side-effects especially at higher doses. For some patients, especially where only one eye is ...
Current concepts on the efficacy of electroconvulsive shock therapy
... factor" or a pattern of symptoms that are commonly found in a series of depressed patients that ce.a·be indentified as the endogenous factor. Mendels and Cochrane 10 reviewed seven such studiest~,li7,1~A 15, whcih attempted to find the "endogenous-reactive factor." Agreement between studies was exam ...
... factor" or a pattern of symptoms that are commonly found in a series of depressed patients that ce.a·be indentified as the endogenous factor. Mendels and Cochrane 10 reviewed seven such studiest~,li7,1~A 15, whcih attempted to find the "endogenous-reactive factor." Agreement between studies was exam ...
What are the differences between non
... the dose and the formulation; mean absorption of around 10 to 30% of a rectal dose has been reported. There is strong evidence from randomised controlled trials to support use of topical mesalazine as a first line treatment for patients with mildly to moderately active distal UC. Guidelines and revi ...
... the dose and the formulation; mean absorption of around 10 to 30% of a rectal dose has been reported. There is strong evidence from randomised controlled trials to support use of topical mesalazine as a first line treatment for patients with mildly to moderately active distal UC. Guidelines and revi ...
Netherlands Journal of Critical Care
... venous distention is usually present but may be absent in cases of hypovolemia. A key finding in cases of cardiac tamponade is pulsus paradoxus (PP)2,4,5. PP, however, is not pathognomonic for tamponade. It may also be present in cases of massive pulmonary embolism, profound haemorrhagic shock, and ...
... venous distention is usually present but may be absent in cases of hypovolemia. A key finding in cases of cardiac tamponade is pulsus paradoxus (PP)2,4,5. PP, however, is not pathognomonic for tamponade. It may also be present in cases of massive pulmonary embolism, profound haemorrhagic shock, and ...
Unstable Angina/ Non–ST-Elevation Myocardial
... results from coronary artery narrowing caused by a nonocclusive thrombus that has developed on a disrupted atherosclerotic plaque. UA and NSTEMI are considered to be closely related conditions whose pathogenesis and clinical presentations are similar but of differing severity; they differ primarily ...
... results from coronary artery narrowing caused by a nonocclusive thrombus that has developed on a disrupted atherosclerotic plaque. UA and NSTEMI are considered to be closely related conditions whose pathogenesis and clinical presentations are similar but of differing severity; they differ primarily ...
Dilatrend
... Inhibitors as well as inducers of CYP2D6 and CYP2C9 can modify the systemic and/or presystemic metabolism of carvedilol stereoselectively, leading to increased or decreased plasma concentrations of R and S-carvedilol (see Pharmacokinetic Properties; Metabolism). Some examples observed in patients or ...
... Inhibitors as well as inducers of CYP2D6 and CYP2C9 can modify the systemic and/or presystemic metabolism of carvedilol stereoselectively, leading to increased or decreased plasma concentrations of R and S-carvedilol (see Pharmacokinetic Properties; Metabolism). Some examples observed in patients or ...
Updates to the Infective Endocarditis Diagnosis and
... http://www.heart.org/idc/groups/heartpublic/@wcm/@hcm/documents/image/~extract/UCM_451092~2~staticrendition/large.jpg ...
... http://www.heart.org/idc/groups/heartpublic/@wcm/@hcm/documents/image/~extract/UCM_451092~2~staticrendition/large.jpg ...
(Zevalin) package insert
... b. The volume of 50 mM Sodium Acetate solution needed is 1.2 times the volume of Y-90 Chloride solution determined in step 3.a, above. c. Calculate the volume of formulation buffer needed to bring the reaction vial contents to a final volume of 10 mL. 4. Transfer the calculated volume of 50 mM Sodiu ...
... b. The volume of 50 mM Sodium Acetate solution needed is 1.2 times the volume of Y-90 Chloride solution determined in step 3.a, above. c. Calculate the volume of formulation buffer needed to bring the reaction vial contents to a final volume of 10 mL. 4. Transfer the calculated volume of 50 mM Sodiu ...
PHARMACOLOGICAL TREATMENT OF HEART FAILURE (HF)
... Because the only reason to treat such patients is to prevent the progression of HF, and because digoxin has minimal effect on disease progression in symptomatic patients, it is unlikely that the drug would be beneficial in those with no symptoms8. Likewise, there are no data to recommend the routine ...
... Because the only reason to treat such patients is to prevent the progression of HF, and because digoxin has minimal effect on disease progression in symptomatic patients, it is unlikely that the drug would be beneficial in those with no symptoms8. Likewise, there are no data to recommend the routine ...
Multiplex MassTag-PCR for respiratory pathogens in pediatric
... in 1, HPIV-2 in 1, and HPIV-3 in 5 patients, suggesting a greater sensitivity than the DFA and culture assays. Conventional RT-PCR detected HBoV in 3 (7%) of 44 specimens. Two of these were co-infected with either HMPV or HPIV-3 (Table 1). The patient co-infected with HMPV was a 16-monthold girl wit ...
... in 1, HPIV-2 in 1, and HPIV-3 in 5 patients, suggesting a greater sensitivity than the DFA and culture assays. Conventional RT-PCR detected HBoV in 3 (7%) of 44 specimens. Two of these were co-infected with either HMPV or HPIV-3 (Table 1). The patient co-infected with HMPV was a 16-monthold girl wit ...
Epley Maneuver in Vertigo
... (Auagnostou et al,. 2013). The results of the study indicate that the Epley maneuver is an effective therapy to implement in order to treat BPPV. Strengths and opportunities of this study were that the Epley maneuver is an effective option to use when treating BPPV and that it is just as effective a ...
... (Auagnostou et al,. 2013). The results of the study indicate that the Epley maneuver is an effective therapy to implement in order to treat BPPV. Strengths and opportunities of this study were that the Epley maneuver is an effective option to use when treating BPPV and that it is just as effective a ...
Management of multiple sclerosis
Several therapies for multiple sclerosis (MS) exist, although there is no known cure. Multiple sclerosis is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS).The most common initial course of the disease is the relapsing-remitting subtype, which is characterized by unpredictable attacks (relapses) followed by periods of relative remission with no new signs of disease activity. After some years, many of the people who have this subtype begin to experience neurologic decline without acute relapses. When this happens it is called secondary progressive multiple sclerosis. Other, less common, courses of the disease are the primary progressive (decline from the beginning without attacks) and the progressive-relapsing (steady neurologic decline and superimposed attacks). Different therapies are used for patients experiencing acute attacks, for patients who have the relapsing-remitting subtype, for patients who have the progressive subtypes, for patients without a diagnosis of MS who have a demyelinating event, and for managing the various consequences of MS.The primary aims of therapy are returning function after an attack, preventing new attacks, and preventing disability. As with any medical treatment, medications used in the management of MS may have several adverse effects, and many possible therapies are still under investigation. At the same time different alternative treatments are pursued by many patients, despite the paucity of supporting, comparable, replicated scientific study.This article focuses on therapies for standard MS; borderline forms of MS have particular treatments that are excluded.